Home » Newsletters » BioWorld Science

BioWorld Science

March 20, 2006

View Archived Issues

Medarex looks back on achievements

Cangrelor demonstrates advantages over abciximab in patients undergoing PCI

Mepolizumab decreases eosinophilia in hypereosinophilic syndromes, esophagitis

Novel anti-HGF MAb L2G7 exhibits profound effects in mice bearing intracranial glioma xenografts

Targeted Genetics supports plans for 2006 through new financing

Dusa closes acquisition of Sirius Laboratories

Pharmos to acquire Vela Pharmaceuticals

Enrollment completed in SPIRIT III study of Xience V stent

Roche expands manufacturing network for production of Tamiflu

GenVec expands TNFerade phase II study into phase II/III trial

Edison and university partners establish mitochondrial disease collaboration

AdvaTab Cetirizine completes pharmacokinetic study

Phase II pilot study assesses Oxycyte in traumatic brain injury

Novavax collaborative HIV program receives additional funding

LymphoSign completes preclinical testing of LS-104

V-1003 superior to Vicodin for pain relief

Significant decline in HBV viral load in pradefovir study

Sativex produces improvement in MS-related spasticity

Human Genome Sciences reports new phase II data for Albuferon

ALK5 inhibitor a novel therapeutic approach for the treatment of fibrosis

Recent patents impart new therapeutic agents for cancer

New agents for treating thrombocythemia reported in recent Shire patent

Targeting the M. tuberculosis proteasome for novel tuberculosis therapies

ARRY-649: A novel, highly potent KSP inhibitor from Array BioPharma

The glycolytic enzyme GAPDH as a target for neuroprotection

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...